U.S., April 3 -- ClinicalTrials.gov registry received information related to the study (NCT06907615) titled 'APhase II Clinical Study to Evaluate HLX43 in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)' on March 26.
Brief Summary: The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
Study Start Date: May 26
Study Type: INTERVENTIONAL
Condition:
Non Small Cell Lung Cancer
Intervention:
DRUG: HLX43 DOSE 1
Dose 1; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
DRUG: ...